News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Nvidia fundamentals remain strong but momentum is compressed and short interest is elevated ahead of 11/17 earnings.
  • Tactical bearish trade recommends inverse product NVDL: entry $205.29, target $180, stop $225, 10-day horizon.
  • Alvotech trades at $4.48 and is priced like a company with a broken-factory narrative.
  • Recent approvals and financing materially boost Alvotech's manufacturing capacity and liquidity.
  • Proposed mid-term long uses a 45-trading-day horizon ahead of Q3 results.

Latest Articles

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Arcutis Biotherapeutics announced that its topical eczema treatment, ZORYVE® (roflumilast) cream 0.15%, received the first-ever Marie Claire Beauty Award for Best Prescription Skin Solution. The award highlights ZORYVE’s innovative non-steroidal formulation designed for mild to moderate atopic dermatitis patients aged 6 and older. This recognition …

ZenaTech Advances ZenaDrone 2000 Heavy-Lift Interceptor Toward Flight Testing for Counter-UAS and Maritime Defense

ZenaTech Advances ZenaDrone 2000 Heavy-Lift Interceptor Toward Flight Testing for Counter-UAS and Maritime Defense

ZenaTech, Inc. announced progress on the ZenaDrone 2000, a heavy-lift autonomous interceptor drone designed to counter hostile drones and swarm attacks over land and sea. The company is completing prototype assembly at its UAE facility and plans to begin flight testing in Q1 2027. The ZenaDrone 2000 aims to provide a cost-effective, long-endurance …

Ocean Power Technologies Demonstrates Offshore Deployment of Greensea IQ Bayonet 150 from Modified WAM-V 16

Ocean Power Technologies Demonstrates Offshore Deployment of Greensea IQ Bayonet 150 from Modified WAM-V 16

Ocean Power Technologies (NYSE American: OPTT) completed a proof of concept by modifying its WAM-V 16 unmanned surface vessel to transport and deploy Greensea IQ's amphibious Bayonet 150 Autonomous Underwater Ground Vehicle offshore. The test demonstrated the vehicles' ability to work in tandem for maritime missions such as mine countermeasures, hi…

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

60 Degrees Pharmaceuticals announced it will conclude enrollment for its clinical trial of tafenoquine in severe babesiosis with 30 patients and plans to unblind and present primary and secondary endpoint results in January 2027. The company will also seek a pre-supplemental New Drug Application (pre-sNDA) meeting with the FDA to discuss regulatory…

Alpha Compute Corp. Signs Agreement with AI Platform to deliver Compute via its ALPHA-02 Cluster in Sweden, with a total value of $71.9 Million

Alpha Compute Corp. Signs Agreement with AI Platform to deliver Compute via its ALPHA-02 Cluster in Sweden, with a total value of $71.9 Million

Alpha Compute Corp., a US-based leader in sovereign super intelligence, has signed a binding $71.9 million contract to deploy its state-of-the-art ALPHA-02 NVIDIA B300 GPU compute cluster in a hydropowered data center in Sweden. This deal ensures long-term utilization of the high-density AI compute capacity ahead of full deployment, reflecting grow…

Global Ship Lease Announces Exercise of Newbuild Options

Global Ship Lease Announces Exercise of Newbuild Options

Global Ship Lease, a NYSE-listed containership owner and lessor, announced it has exercised options to build two additional state-of-the-art, mid-size, ultra-high-reefer, wide-beam containerships for approximately $163 million, with delivery scheduled in Q4 2029. This decision increases its newbuilding orderbook to 17 ships, aligning with its strat…

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Collegium Pharmaceutical, a Nasdaq-listed biopharmaceutical firm, has launched Start Talking ADHD, an online resource with practical guides to assist patients and families managing ADHD in healthcare, education, and daily life contexts. The initiative accompanies Collegium's recent expansion of its ADHD medication portfolio, underscoring the compan…

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Madrigal Pharmaceuticals announced publication of a secondary analysis from their Phase 3 MAESTRO-NASH trial demonstrating that Rezdiffra (resmetirom) effectively improves liver histology, reduces fibrosis, and lowers liver fat and biomarkers across multiple genetic variants associated with metabolic dysfunction-associated steatohepatitis (MASH). T…

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Akebia Therapeutics announced multiple presentations at the ASN Kidney Week 2026, including a late-breaking presentation of the VOICE trial assessing vadadustat for anemia in hemodialysis patients, as well as posters on their rare kidney disease pipeline and clinical and economic outcomes for their drug Vafseo (vadadustat). These updates underscore…

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

LB Pharmaceuticals Inc (Nasdaq: LBRX) announced an in-person and virtual R&D Day on October 27, 2026, focusing on its lead investigational drug LB-102, a novel antipsychotic in Phase 3 development for schizophrenia. The event will feature presentations from key company executives and prominent psychiatrist Dr. Roger S. McIntyre, providing scientifi…

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Entera Bio Ltd., a clinical-stage biopharmaceutical company developing oral peptide therapies, has appointed Laura Hamill, an experienced global commercial leader from Gilead Sciences and Amgen, to its Board of Directors effective December 1, 2026. This strategic move aims to leverage her expertise to support Entera’s late-stage clinical developmen…

Rezolve Ai Showcases Agentic Commerce Platform at Nasdaq Investor Day and Publishes U.S. AI Visibility Study

Rezolve Ai Showcases Agentic Commerce Platform at Nasdaq Investor Day and Publishes U.S. AI Visibility Study

Rezolve Ai, listed on NASDAQ as RZLV, hosted its Investor Day at the Nasdaq MarketSite showcasing its full agentic commerce platform with live demonstrations and revealing key findings from its US AI Visibility Study 2026. The study highlights a significant gap in AI agent engagement among America's largest retailers, underscoring the necessity for…

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio Limited (Nasdaq: YDES) and EG BioMed have introduced an AI-based online cancer risk assessment tool that evaluates individual self-reported health data to generate personalized risk reports for ten major cancer types. This tool integrates with their oncology services and aims to empower users with insights for informed healthcare discussions…

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

vTv Therapeutics announced a virtual key opinion leader event scheduled for October 20, 2026, featuring diabetes experts and patient advocates to discuss challenges in type 1 diabetes, hypoglycemia risk, and the company's phase 3 trial of cadisegliatin, an oral glucokinase activator. The event aims to provide insights into the ongoing CATT1 trial w…

NANO Nuclear Energy Appoints Former Y-12 Leader and Nuclear Fuel Cycle Expert Jennifer Charlton, Ph.D., as Vice President of Fuel Technology to Accelerate Vertical Integration Strategy

NANO Nuclear Energy Appoints Former Y-12 Leader and Nuclear Fuel Cycle Expert Jennifer Charlton, Ph.D., as Vice President of Fuel Technology to Accelerate Vertical Integration Strategy

NANO Nuclear Energy Inc. announced the hiring of Jennifer Charlton, Ph.D., a seasoned nuclear fuel cycle expert and former Y-12 National Security Complex leader, as Vice President of Fuel Technology. This strategic appointment aims to accelerate NANO Nuclear's vertical integration across the nuclear fuel cycle, supporting its advanced micro modular…

Pasqal Reaffirms its Commitment to the EU’s Quantum Ambitions as It Leads Q-PLANET for Neutral-Atom Technologies

Pasqal Reaffirms its Commitment to the EU’s Quantum Ambitions as It Leads Q-PLANET for Neutral-Atom Technologies

Pasqal has taken a leading role in the Q-PLANET consortium, which is funded with €50 million by the EU Chips Joint Undertaking and national authorities. The initiative aims to develop industrial-grade chip components for neutral-atom quantum computing, sensing, and communication over the next three years. This effort supports the European Union's s…